Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Educating immune system may ease future use of stem cells

20.07.2004


Results of laboratory experiments by Johns Hopkins scientists suggest it may be possible to "educate" the immune system to recognize rather than destroy human embryonic stem cells. Doing so could reduce the risk of rejection if the primitive cells are someday transplanted into people with conditions like Parkinson’s disease, diabetes or spinal cord injuries, the researchers say.

In their experiments, described in the July 10 issue of The Lancet, the Hopkins team successfully coaxed human embryonic stem cells to become the special "flag-waving" cells that tell the immune system what is "friend" and what is "foe." In additional experiments in the lab, the researchers found that these so-called antigen presenting cells can control the responses of other immune cells, called T cells, whose job is either to attack or to co-exist with "foreign" cells.

"This is the first evidence that human embryonic stem cells can generate antigen presenting cells that could be used to educate a patient’s immune system," says Linzhao Cheng, Ph.D., assistant professor in Johns Hopkins’ Institute for Cell Engineering. "It’s a small but important step toward future clinical use of the stem cells, but many challenges remain."



Because all human cells carry proteins that identify them as coming from a particular person, even embryonic stem cells could be rejected if their identifying proteins, or antigens, don’t exactly match the recipients’.

But matching embryonic stem cells to potential recipients carries ethical dilemmas for many, since it might require destruction of more in vitro fertilized embryos to get new embryonic stem cell lines or attempting so-called therapeutic cloning (somatic cell nuclear transfer), which would use an individual’s regular cells to create the early embryos from which stem cells are derived. Cheng adds that the science is far from making the latter a practical option, and notes that neither approach provides an exact match for patients.

Even the use of powerful immune-suppressing drugs, such as those used for organ and tissue transplant recipients, would require better "matches" than today’s limited selection of embryonic stem cells can provide, says Cheng.

A paper by Hopkins researchers and others last fall suggests that to provide embryonic stem cells that acceptably and equitably match an equal percentage of various ethnic groups, at least 85 carefully selected stem cell lines would need to be established. There are currently just a few dozen validated lines of human embryonic stem cells, most scientists think.

Because of the stem cells’ flexibility, however, some scientists are trying to make the cells "stealthy" so they might escape detection by the immune system, even if they don’t perfectly match the patient. One potential stealth-inducing technique is to modify or replace the genes in the embryonic stem cell that control production of rejection-inducing proteins, but progress has been slow, Cheng says.

His team is also pursuing a second option — using the embryonic stem cells to get special immune cells. Because both the immune cells and the therapeutic cells — say pancreatic islet cells for a type I diabetic, or dopamine-producing neurons for a person with Parkinson’s disease — would be derived from the same embryonic stem cell line, they would match one another. And the immune cells then could tell the patient’s immune system that the transplanted therapeutic cells "belong."

"In some clinical situations, studies have demonstrated that if you can get immune cells to recognize the transplanted tissue as ’friend,’ then the chances of rejection are lower," says Cheng.

For example, transplanting bone marrow from an organ donor into the recipient, at the same time as or prior to transplantation of the needed organ — say, a kidney — has been associated with reduced rejection, says Cheng. The transplanted bone marrow cells co-exist with the patient’s own tissue and essentially create a new corner of the patient’s immune system that recognizes the transplanted organ as self.

"We’re presenting the first, very early suggestion that the same idea might be applicable to future applications of embryonic stem cells," says Cheng. "There still are many challenges ahead to know whether this will apply to potential uses of embryonic stem cells, but it’s important to try to address the issues of ’matching’ and rejection before the cells reach the clinic."

By bathing the human embryonic stem cells in a soup of certain proteins known to encourage the cells’ progression into various types of blood cells, postdoctoral fellows Xiangcan Zhan and Gautam Dravid and their colleagues coaxed the primitive cells to become antigen presenting cells, sentries that tell other immune cells whether to destroy or spare cells they meet. In additional experiments, the researchers also showed that these antigen presenting cells worked as they should, at least in the lab.

"The idea is that you would create a large number of the antigen presenting cells and related immune cells and give those to the patient before they get another cell type from the same embryonic stem cell line," says Cheng. "Then, the patient’s immune system would include cells that recognize the transplanted cells, preventing their destruction."

Animal experiments to prove that these human antigen presenting cells can really induce immune tolerance will be very difficult to do, he says, since any human cell would be attacked by a mouse’s immune system. Cheng says that his lab will continue looking for evidence of specific immunity and of immune tolerance induced in laboratory dishes of human embryonic stem cells.

Joanna Downer | EurekAlert!
Further information:
http://www.jhmi.edu
http://www.hopkinsmedicine.org/ice

More articles from Life Sciences:

nachricht Switch-in-a-cell electrifies life
18.12.2018 | Rice University

nachricht Plant biologists identify mechanism behind transition from insect to wind pollination
18.12.2018 | University of Toronto

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Data storage using individual molecules

Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.

Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...

Im Focus: Data use draining your battery? Tiny device to speed up memory while also saving power

The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.

Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

Pressure tuned magnetism paves the way for novel electronic devices

18.12.2018 | Materials Sciences

New type of low-energy nanolaser that shines in all directions

18.12.2018 | Physics and Astronomy

NASA research reveals Saturn is losing its rings at 'worst-case-scenario' rate

18.12.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>